Clinical Trials Logo

Filter by:
NCT ID: NCT06345781 Not yet recruiting - Clinical trials for Spinal Cord Injuries

Abdominal Functional Electrical Stimulation to Improve Bowel Function in Spinal Cord Injury

Start date: April 2024
Phase: N/A
Study type: Interventional

The primary objective of this study is to gather information about the effectiveness of abdominal FES to improve bowel management time (BMT) for people with chronic SCI. This study will also evaluate whether abdominal FES can improve: 1) bowel-related quality of life, 2) participant-reported bowel function, 3) bowel management strategy, 4) bladder symptoms, and 5) unplanned hospital admissions. In addition, we will also explore participant perspectives and experiences about the stimulation sessions and use of the device.

NCT ID: NCT06345755 Recruiting - Clinical trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Start date: April 17, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

NCT ID: NCT06345729 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Start date: May 31, 2024
Phase: Phase 3
Study type: Interventional

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).

NCT ID: NCT06345690 Recruiting - Back Pain Clinical Trials

VIA Disc NP Registry 3.0

Start date: February 27, 2024
Phase:
Study type: Observational [Patient Registry]

Registry is to observe and trend patterns of care and outcomes for patients treated with VIA Disc NP.

NCT ID: NCT06345638 Enrolling by invitation - Sickle Cell Disease Clinical Trials

Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease

Start date: March 1, 2024
Phase:
Study type: Observational

This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD). - The study will compare CRP and other biomarkers between females with SCD in the follicular phase of the menstrual cycle and males with SCD. - The study will explore potential sex differences in biomarker changes between females and males with SCD during and following resolution of VOC. - The study will compare neutrophil and platelet adhesion to the endothelium and real time fibrin deposition in the blood.

NCT ID: NCT06345495 Not yet recruiting - Myelofibrosis Clinical Trials

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

NCT ID: NCT06345443 Not yet recruiting - Vascular Stiffness Clinical Trials

NRM on Vascular Perfusion in Healthy Adults

NRM
Start date: June 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.

NCT ID: NCT06345404 Recruiting - Atopic Dermatitis Clinical Trials

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Start date: April 2024
Phase: Phase 1
Study type: Interventional

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

NCT ID: NCT06345339 Recruiting - Hypothyroidism Clinical Trials

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Start date: April 26, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.

NCT ID: NCT06345274 Not yet recruiting - Opioid Use Disorder Clinical Trials

MBC2OTP Project (Measurement-Based Care Implementation in Community Opioid Treatment Programs)

MBC2OTP
Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the effectiveness and implementation of measurement-based care, which involves the systematic use of client self-report data to inform and enhance treatment, in opioid treatment programs using a pilot hybrid effectiveness-implementation study design. The main questions this study aims to answer are: 1) is measurement based care effective for improving patient treatment attendance and opioid abstinence, and 2) can measurement based care be implemented with fidelity in opioid treatment programs? Participants in this study will be opioid treatment program leaders and treatment providers. Leaders and treatment providers will participate in measurement-based care implementation strategies such as training and consultation to help them use measurement-based care with their patients. There is no comparison group for this study, however researchers will compare effectiveness outcomes prior to and post measurement-based care implementation and will evaluate changes in measurement-based care use with fidelity post implementation.